Loading clinical trials...

ADYNOVATE Drug Use-Results Survey | Clinical Trials | Clareo Health

COMPLETED

ADYNOVATE Drug Use-Results Survey

NCT03169972•Takeda

Summary

The purpose of this survey is to understand the following items in the actual clinical use of ADYNOVATE in patients: 1. Unexpected adverse drug reactions 2. Occurrence of adverse drug reactions in the actual clinical use 3. Factors that may affect safety and efficacy 4. Occurrence of Factor VIII inhibitor development in patients with coagulation factor VIII deficiency (hereinafter hemophilia A) 5. Safety and efficacy for hemophilia A patients who received routine prophylactic therapy and on-demand therapy

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Hemophilia A patients who receive ADYNOVATE, including previously treated patients with Factor VIII deficiency (PTPs), and previously untreated patients with Factor VIII deficiency (PUPs) who are treated with ADYNOVATE.

Exclusion Criteria

•Patients not administered ADYNOVATE.

Locations (52)

Nagoya City, Japan

Nagoya, Aichi-ken, Japan

Hirosaki City

Hirosaki, Aomori, Japan

Chiba-City, Japan

Chiba, Chiba, Japan

Matsudo City, Japan

Matsudo, Chiba, Japan

Narita City

Narita, Chiba, Japan

Matsuyama City, Japan

Matsuyama, Ehime, Japan

Toon City

Tōon, Ehime, Japan

Fukuoka-City, Japan

Fukuoka, Fukuoka, Japan

Kitakyusyu City, Japan

Kitakyushu, Fukuoka, Japan

Kitakyusyu City, Japan

Kitakyushu, Fukuoka, Japan

Key Dates

Start Date

February 1, 2017

Primary Completion Date

September 15, 2023

Completion Date

September 15, 2023

Last Updated

February 4, 2025

Enrollment

135

ACTUAL participants

Conditions

Hemophilia A

Interventions

ADYNOVATE

BIOLOGICAL

A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

NCT07226206

Hemophilia A

View study

RECRUITINGPHASE1/PHASE2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

NCT05987449

Hemophilia A

View study

RECRUITING

National Longitudinal Cohort of Hematological Diseases

NCT04645199

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 4, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

ADYNOVATE Drug Use-Results Survey

Inclusion Criteria

Exclusion Criteria

A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

National Longitudinal Cohort of Hematological Diseases

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

Home Monitoring in Hemophilia a

Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A